Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olmesartan Medoxomil

FDA-approved product (tablet, oral), marketed as Benicar, Olmesartan Medoxomil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olmesartan Medoxomil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olmesartan Medoxomil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olmesartan Medoxomil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Polypills Approach for Multiple Cardiovascular Risk Factors

    NCT07679828 · start 2026-07-11

    Registered record
    Registry ID
    NCT07679828
    Conditions
    Hypertension; Dyslipidemia; Diabetes
    Interventions
    Fixed-Dose Combination Strategy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-11
    Completion
    2030-03-01
    Enrolment
    8,252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia; Diabetes
    InterventionFixed-Dose Combination Strategy
    PhaseNot applicable
    Registry statusRecruiting

  • Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

    NCT07810088 · start 2025-06-28

    Registered record
    Registry ID
    NCT07810088
    Conditions
    HR+ / HER2- Advanced Breast Cancer
    Interventions
    Treatment; Treatment; Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-28
    Completion
    2028-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHR+ / HER2- Advanced Breast Cancer
    InterventionTreatment; Treatment; Treatment
    PhasePhase 2
    Registry statusRecruiting

  • Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

    NCT05917275 · start 2024-04-04

    Registered record
    Registry ID
    NCT05917275
    Conditions
    Primary Hypertension
    Interventions
    Amlodipine; Olmesartan; Hydrochlorothiazide; Amlodipine/Olmesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-04-04
    Completion
    2025-10
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypertension
    InterventionAmlodipine; Olmesartan; Hydrochlorothiazide; Amlodipine/Olmesartan
    PhasePhase 4
    Registry statusUnknown

  • Optimal Medical Treatment of Difficult-to-treat Hypertension

    NCT06275763 · start 2023-10-20

    Registered record
    Registry ID
    NCT06275763
    Conditions
    Hypertension
    Interventions
    Phase C: Eplerenone; Phase C: Spironolactone; Phase C: Torasemide; Phase B: Triplixam / Elestar HCT; Phase A: Confirmation of uncontrolled hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-10-20
    Completion
    2025-12-31
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionPhase C: Eplerenone; Phase C: Spironolactone; Phase C: Torasemide; Phase B: Triplixam / Elestar HCT +1 more
    PhasePhase 4
    Registry statusUnknown

  • Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

    NCT05411887 · start 2022-06-20

    Registered record
    Registry ID
    NCT05411887
    Conditions
    Hyperlipidemias; Hypertension
    Interventions
    Rosuvastatin, Olmesartan Medoxomil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-06-20
    Completion
    2025-12-31
    Enrolment
    2,845

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemias; Hypertension
    InterventionRosuvastatin, Olmesartan Medoxomil
    PhaseNot recorded
    Registry statusActive not recruiting

  • Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

    NCT05017987 · start 2021-06-19

    Registered record
    Registry ID
    NCT05017987
    Conditions
    Healthy Adult Volunteers
    Interventions
    ATB-101, ATB-1011, ATB-1012
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-19
    Completion
    2021-07-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Volunteers
    InterventionATB-101, ATB-1011, ATB-1012
    PhasePhase 1
    Registry statusCompleted

  • Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

    NCT05189015 · start 2021-01-01

    Registered record
    Registry ID
    NCT05189015
    Conditions
    Angiotensin/Renin/Aldosterone Hypertension; Hypertension; Diabetes Mellitus, Type 2
    Interventions
    Olmesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2023-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngiotensin/Renin/Aldosterone Hypertension; Hypertension; Diabetes Mellitus, Type 2
    InterventionOlmesartan
    PhasePhase 4
    Registry statusCompleted

  • Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

    NCT04606563 · start 2020-10-09

    Registered record
    Registry ID
    NCT04606563
    Conditions
    Covid19; SARS-CoV Infection
    Interventions
    Losartan; Valsartan; Azilsartan; Candesartan; Eprosartan; Irbesartan; Olmesartan; Telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-10-09
    Completion
    2022-04-22
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection
    InterventionLosartan; Valsartan; Azilsartan; Candesartan +4 more
    PhasePhase 3
    Registry statusTerminated

  • Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke

    NCT03655964 · start 2018-08-20

    Registered record
    Registry ID
    NCT03655964
    Conditions
    Stroke, Ischemic
    Interventions
    Olmesartan; Nebivolol; No antihypertensive treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-20
    Completion
    2019-08-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke, Ischemic
    InterventionOlmesartan; Nebivolol; No antihypertensive treatment
    PhasePhase 2
    Registry statusCompleted

  • Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

    NCT02848170 · start 2016-08

    Registered record
    Registry ID
    NCT02848170
    Conditions
    Essential Hypertension
    Interventions
    CS-3150; olmesartan medoxomil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-08
    Completion
    2017-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionCS-3150; olmesartan medoxomil
    PhaseNot applicable
    Registry statusCompleted

  • Study of DWJ1351 in Healthy Male Volunteers

    NCT02665832 · start 2016-01

    Registered record
    Registry ID
    NCT02665832
    Conditions
    Healthy
    Interventions
    DWJ1351; Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2016-06
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDWJ1351; Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
    PhasePhase 1
    Registry statusUnknown

  • Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

    NCT02996916 · start 2015-12

    Registered record
    Registry ID
    NCT02996916
    Conditions
    Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension
    Interventions
    Olmesartan; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2020-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEfficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension
    InterventionOlmesartan; Amlodipine
    PhasePhase 4
    Registry statusUnknown

  • Azilsartan in Chinese Patients With Mild and Moderate Hypertension

    NCT02609490 · start 2015-09

    Registered record
    Registry ID
    NCT02609490
    Conditions
    Hypertension
    Interventions
    Azilsartan tablets; Azilsartan placebo tablets; Olmesartan medoxomil tablets; olmesartan medoxomil placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2018-08
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAzilsartan tablets; Azilsartan placebo tablets; Olmesartan medoxomil tablets; olmesartan medoxomil placebo tablets
    PhasePhase 3
    Registry statusCompleted

  • RAS Peptide Profiles in Patients With Arterial Hypertension

    NCT02449811 · start 2015-04

    Registered record
    Registry ID
    NCT02449811
    Conditions
    Essential Hypertension
    Interventions
    Perindopril; Olmesartan; Amlodipine; Hydrochlorothiazide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04
    Completion
    2018-11
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionPerindopril; Olmesartan; Amlodipine; Hydrochlorothiazide
    PhaseNot recorded
    Registry statusCompleted

  • Lowering Blood Pressure in Primary Care in Vienna

    NCT02377661 · start 2015-03

    Registered record
    Registry ID
    NCT02377661
    Conditions
    Hypertension
    Interventions
    Olmesartan medoxomil, amlodipine, hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-05-30
    Enrolment
    229

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOlmesartan medoxomil, amlodipine, hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted